While Parp inhibitors are transforming the treatment of ovarian cancer – at least for a subgroup of patients – the same cannot be said of checkpoint blockers. And on Friday one of the few anti-PD-(L)1 agents with an active programme in this tumour type, Merck KGaA/Pfizer’s Bavencio, flunked its first-line study, Javelin Ovarian 100. This trial had progression-free survival as its primary endpoint, but interim analysis suggested futility, causing it to be terminated. Javelin Ovarian 200, Bavencio’s study in platinum-refractory disease, continues, as do trials in combination with Parp inhibitors. But a search of clinicaltrials.gov reveals a very low-key industry presence overall, with the vast majority of checkpoint blocker studies in ovarian cancer being sponsored by academia. Other notable exceptions include the uncontrolled Keynote-100 trial of Merck & Co’s Keytruda in second-line disease, and the phase III Imagyn-050 test of Roche’s Tecentriq in combination with Avastin, in front-line treatment of tumours that also include fallopian tube and primary peritoneal cancers.
|Failed studies of anti-PD-(L)1 antibodies across various cancer types|
|Merck & Co||Bristol-Myers Squibb||Roche||Astrazeneca||Merck KGaA/Pfizer|
|NSCLC||Checkmate-026 (1L)||Arctic (3L)
|Javelin Lung 200 (2L)|
|Head & neck||Keynote-040 (2L)||Eagle (2L)*|
|Ovarian||Javelin Ovarian 100 (1L)|
|*CTLA-4 combo; **Cotellic combo; 1L=1st line; 2L=2nd line; 3L=3rd line.|